Background: Treatment options for metastatic renal cell carcinoma (mRCC) have improved over recent years. Various therapies for metastatic renal cell carcinoma are currently approved for first and successive lines. Having various treatment options makes it important to reflect how patients experience side effects in the real-world setting.
View Article and Find Full Text PDFPurpose: The treatment landscape in metastatic renal cell carcinoma (mRCC) has evolved dramatically in recent years. Within the German guideline committee for RCC we evaluated current medical treatments and gave recommendations.
Methods: A systematic review of published evidence for medical treatment of mRCC was performed (July 2016-August 2019) to cover the duration from last guideline update in 2016.
Objectives: The aim was to assess differences in age, gender, education and personality (Big Five) between cancer patients already interested in CAM prior to the diagnosis and cancer patients only interested in CAM since their diagnosis.
Design: 323 members of the support and information platform "Lebenshaus e.V.
To learn more about information needs and satisfaction with provided information among cancer patients and whether dissatisfaction with information has any association with how therapy decisions are made. An online survey was conducted during March 2015 and January 2016 by the German non-profit patient organization "Das Lebenshaus e.V.
View Article and Find Full Text PDFObjective: 40-50% of German cancer patients use some method of complementary and alternative medicine (CAM) and both patients and doctors often feel insufficiently informed. We examined the information-seeking behaviour and satisfaction with information on patients' interest in CAM and the therapy decision.
Design And Setting: An anonymous, voluntary online survey was conducted among the members of "Das Lebenshaus e.